Table 5Sample, duration, length of followup, and attrition in randomized controlled clinical trials that examined migraine prevention in children

Drug References for RCTs*Duration of Run-In Period, Weeks
# RCTs / Mean
[Min to Max]
Total Sample Assigned to Treatment
# RCTs / Mean
[Min to Max]
Total Length of Followup, Weeks
# RCTs / Mean
[Min to Max]
Loss of Followup in Control Group, %
# RCTs / Mean
[Min to Max]
Loss of Followup in Active Group, %
# RCTs / Mean
[Min to Max]
Topiramate81-875 / 7.2
[4.0 to 9.0]
7 / 75.4
[14.0 to 162.0]
7 / 17.7
[12.0 to 26.0]
3 / 12.3
[4.0 to 24.7]
3 / 8.7
[4.5 to 11.4]
Divalproex69,73,961 / 6.01 / 305.01 / 12.01 / 5.51 / 3.9
Valproate8801 / 120.01 / 12.000
Propranolol77-802 / 4.0
[4.0 to 4.0]
4 / 45.3
[32.0 to 63.0]
4 / 27.8
[24.0 to 35.0]
2 / 4.4
[3.3 to 5.5]
2 / 4.2
[3.3 to 5.1]
Metoprolol751 / 4.01 / 43.01 / 32.000
Trazodone701 / 4.01 / 40.01 / 28.000
Nimodipine7601 / 37.01 / 28.000
Clonidine71,7202 / 54.0
[51.0 to 57.0]
2 / 16.0
[8.0 to 24.0]
1 / 9.81 / 9.8
Magnesium741 / 4.01 / 118.01 / 16.000
Drug management8901 / 68.01 / 6.00
Total11 / 5.5
[4.0 to 9.0]
20 / 75.73
[14.0 to 305.0]
20 / 19.9
[6.0 to 35.0]
7 / 8.7
[3.3 to 24.7]
7 / 6.5
[3.3 to 11.4]

RCT = randomized controlled trials

*

include multiple publications of RCTs.

From: Results

Cover of Migraine in Children: Preventive Pharmacologic Treatments
Migraine in Children: Preventive Pharmacologic Treatments [Internet].
Comparative Effectiveness Reviews, No. 108.
Shamliyan TA, Kane RL, Ramakrishnan R, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.